The Valley Desk

NCT01763164 · Interventional trial

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Overall registry status Completed

Phase 3

Conditions Metastatic or Unresectable Cutaneous Melanoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov